Biotech Values

[spartex]

Thanks Dew.

<Is that a fair statement? After all, it’s not that long ago that DNDN was in the mid 4’s and now it’s one-third higher at around 6.>

In light of DNDN's cash position and the fact that it is near another significant trial III announcement, I believe my statement is fair that DNDN is lagging the biotech sector, as well as other companies of similiar size and cash value. In fact, DNDN is much closer to a marketable drug/procedure than the others. Just take a look at the 1 year (or 6 mo) for SCLN, CEGE, REGN and DNDN as a few to compare.

The REGN news is for starting of a Trial I, while DNDN is awaiting a very important Trial III result. The market seems to be shying away from the one that is closest to reaching a marketable product. Now that is odd to me, but I realize Mr. Market can be a strange bird from time to time and misprice until there is enough evidence to "buy".

http://finance.yahoo.com/q/bcs=DNDN&t=1y&l=on&z=m&q=l&c=cege,regn,scln

Good luck and thanks for your thoughts, Spartex